Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer

OBJECTIVE: Activating KRAS mutations are the most common drivers in the development of non-small cell lung cancer (NSCLC). However, unsuccess of treatment by direct inhibition of KRAS has been proven. Deregulation of PI3K signaling plays an important role in tumorigenesis and drug resistance in NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuxiang, Li, Xian, Liu, Xueling, Chen, Yi, Yang, Chunhao, Tan, Cun, Wang, Bobo, Sun, Yiming, Zhang, Xi, Gao, Yinglei, Ding, Jian, Meng, Linghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528459/
https://www.ncbi.nlm.nih.gov/pubmed/31119047
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528459/
https://www.ncbi.nlm.nih.gov/pubmed/31119047
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0361

Ejemplares similares